Our study discovered that high expression of NFATC4 was associated with poor prognosis of AML, which was consistent with reports in pancreatic cancer and ovarian cancer (Hessmann et al., 2016; Cole et al., 2020). Here, NFATC4 is linked to pancreatic neoplasm.